Sobral Margarida, Oliveira Susana
Universidade do Porto, Health Research and Innovation (RISE-Health), Instituto de Ciências Biomédicas de Abel Salazar, Porto, Portugal.
Unidade Local de Saúde de Santo António, Hospital de Magalhães Lemos, Serviço de Psicogeriatria, Porto, Portugal.
Dement Neuropsychol. 2025 Jun 2;19:e20240219. doi: 10.1590/1980-5764-DN-2024-0219. eCollection 2025.
Alzheimer's disease (AD) has significant physical, psychological, and socioeconomic impacts, shortens life expectancy, and reduces quality of life. Non-pharmacological interventions (NPIs) in dementia provide health gains.
The aim of this study was to conduct a cost-utility study of NPIs in AD, assessing both the costs and health gains associated with cognitive stimulation interventions in AD patients.
A sample of 40 patients undergoing NPIs and another 40 individuals (control group) were included. Data collected included sociodemographic, clinical, cognitive, and functional information, as well as health status, quality of life, and outpatient costs.
The NPI, considering the discounted cost value of €21,621.31 and the discounted quality-adjusted life year (QALY) gain of 0.81333, resulted in an estimated cost per QALY of €26,583.76. This cost per QALY is within the threshold generally considered acceptable by regulatory authorities in Portugal and in several European countries.
This study supports the recommendation that interventions adjusted to the needs of patients with AD should be implemented, which may include NPIs providing both health gains and economic value.
阿尔茨海默病（AD）具有重大的身体、心理和社会经济影响，缩短预期寿命并降低生活质量。痴呆症的非药物干预（NPIs）可带来健康益处。
本研究旨在对AD的NPIs进行成本效用研究，评估与AD患者认知刺激干预相关的成本和健康益处。
纳入40名接受NPIs的患者样本以及另外40名个体（对照组）。收集的数据包括社会人口统计学、临床、认知和功能信息，以及健康状况、生活质量和门诊费用。
考虑到贴现成本值为21,621.31欧元以及贴现质量调整生命年（QALY）增益为0.81333，NPIs导致每QALY的估计成本为26,583.76欧元。这个每QALY成本在葡萄牙和几个欧洲国家监管机构通常认为可接受的阈值范围内。
本研究支持应实施根据AD患者需求调整的干预措施这一建议，其中可能包括既带来健康益处又具有经济价值的NPIs。
